Vir Biotechnology, Inc. VIR Proceeds from disposition of marketable securities and other investments
Proceeds from disposition of marketable securities and other investments at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s proceeds from disposition of marketable securities and other investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s proceeds from disposition of marketable securities and other investments?
- Vir Biotechnology, Inc. (VIR) reported proceeds from disposition of marketable securities and other investments of $170.6M in Q1 2026.
- How has Vir Biotechnology, Inc.'s proceeds from disposition of marketable securities and other investments changed year-over-year?
- Vir Biotechnology, Inc.'s proceeds from disposition of marketable securities and other investments decreased by 43.5% year-over-year, from $301.86M to $170.6M.
- What is the long-term trend for Vir Biotechnology, Inc.'s proceeds from disposition of marketable securities and other investments?
- Over 4 years (2021 to 2025), Vir Biotechnology, Inc.'s proceeds from disposition of marketable securities and other investments has grown at a 41.3% compound annual growth rate (CAGR), from $301.24M to $1.2B.